{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:14Z","timestamp":1790677394928,"version":"4.1.0"},"reference-count":168,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2020,1,22]]},"DOI":"10.3233\/jnd-190426","type":"journal-article","created":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T11:15:47Z","timestamp":1574766947000},"page":"15-31","source":"Crossref","is-referenced-by-count":64,"title":["Advancements in AAV-mediated Gene Therapy for Pompe Disease"],"prefix":"10.1177","volume":"7","author":[{"given":"S.M.","family":"Salabarria","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, Floria, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Nair","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, Floria, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Clement","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, Floria, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.K.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Physical Therapy and Center for Respiratory Research and Rehabilitation, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Raben","sequence":"additional","affiliation":[{"name":"Laboratory of Protein Trafficking and Organelle Biology, Cell and Developmental Biology Center, National Heart, Lung and Blood Institute, NIH, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.D.","family":"Fuller","sequence":"additional","affiliation":[{"name":"Department of Physical Therapy and Center for Respiratory Research and Rehabilitation, University of Florida, Gainesville, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.J.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, Floria, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Corti","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Powell Gene Therapy Center, University of Florida, Gainesville, Floria, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"4","key":"10.3233\/JND-190426_ref1","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe Disease: From Basic Science to Therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.3233\/JND-190426_ref2","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.resp.2013.06.007","article-title":"The respiratory neuromuscular system in Pompe disease","volume":"189","author":"Fuller","year":"2013","journal-title":"Respir Physiol Neurobiol"},{"key":"10.3233\/JND-190426_ref3","doi-asserted-by":"crossref","unstructured":"Prosser LA , et al. Using Decision Analysis to Support Newborn Screening Policy Decisions: A Case Study for Pompe Disease. MDM Policy Pract. 2018;3(1).","DOI":"10.1177\/2381468318763814"},{"issue":"3","key":"10.3233\/JND-190426_ref4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","article-title":"The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants","volume":"21","author":"Wasserstein","year":"2019","journal-title":"Genet Med"},{"issue":"1","key":"10.3233\/JND-190426_ref5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","volume":"160C","author":"Kroos","year":"2012","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"1","key":"10.3233\/JND-190426_ref6","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/(SICI)1098-1004(1997)9:1<17::AID-HUMU3>3.0.CO;2-M","article-title":"Two extremes of the clinical spectrum of glycogen storage disease type II in one family: A matter of genotype","volume":"9","author":"Kroos","year":"1997","journal-title":"Hum Mutat"},{"issue":"2","key":"10.3233\/JND-190426_ref7","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"key":"10.3233\/JND-190426_ref8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"Gungor","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"Pt 3","key":"10.3233\/JND-190426_ref9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe\u2019s disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"issue":"6","key":"10.3233\/JND-190426_ref10","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1183\/09031936.05.00020005","article-title":"Respiratory insufficiency and limb muscle weakness in adults with Pompe\u2019s disease","volume":"26","author":"Pellegrini","year":"2005","journal-title":"Eur Respir J"},{"issue":"7","key":"10.3233\/JND-190426_ref11","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1002\/ajmg.a.37687","article-title":"Death from supine asphyxia in late onset pompe disease: Two patients","volume":"170","author":"Kansagra","year":"2016","journal-title":"Am J Med Genet A"},{"issue":"R1","key":"10.3233\/JND-190426_ref12","doi-asserted-by":"crossref","first-page":"R61","DOI":"10.1093\/hmg\/ddr174","article-title":"Pompe disease gene therapy","volume":"20","author":"Byrne","year":"2011","journal-title":"Hum Mol Genet"},{"issue":"1","key":"10.3233\/JND-190426_ref13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: Design, methodology, and early findings from the Pompe Registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"12","key":"10.3233\/JND-190426_ref14","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","article-title":"Effect of enzyme therapy in juvenile patients with Pompe disease: A three-year open-label study","volume":"20","author":"van Capelle","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"10.3233\/JND-190426_ref15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ymgme.2012.08.013","article-title":"Effect of rapid cessation of enzyme replacement therapy: A report of 5 cases and a review of the literature","volume":"107","author":"Jurecka","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.3233\/JND-190426_ref16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: A systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J Neurol"},{"issue":"8","key":"10.3233\/JND-190426_ref17","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/gim.2012.61","article-title":"Correction of a short cardiac PR interval in a 12-year-old girl with late-onset Pompe disease following enzyme replacement therapy","volume":"14","author":"Fernandez","year":"2012","journal-title":"Genet Med"},{"issue":"11","key":"10.3233\/JND-190426_ref18","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.cardfail.2011.07.011","article-title":"Left ventricular geometry, global function, and dyssynchrony in infants and children with pompe cardiomyopathy undergoing enzyme replacement therapy","volume":"17","author":"Chen","year":"2011","journal-title":"J Card Fail"},{"issue":"1","key":"10.3233\/JND-190426_ref19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-018-0824-4","article-title":"Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients","volume":"13","author":"van der Meijden","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.3233\/JND-190426_ref20","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.ymgme.2011.06.010","article-title":"Rapid progressive course of later-onset Pompe disease in Chinese patients","volume":"104","author":"Yang","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"4","key":"10.3233\/JND-190426_ref21","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI1722","article-title":"Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail","volume":"101","author":"Kikuchi","year":"1998","journal-title":"J Clin Invest"},{"issue":"1-2","key":"10.3233\/JND-190426_ref22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ymgme.2003.08.022","article-title":"Enzyme replacement therapy in the mouse model of Pompe disease","volume":"80","author":"Raben","year":"2003","journal-title":"Mol Genet Metab"},{"issue":"3","key":"10.3233\/JND-190426_ref23","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2016.12.004","article-title":"The emerging phenotype of late-onset Pompe disease: A systematic literature review","volume":"120","author":"Chan","year":"2017","journal-title":"Mol Genet Metab"},{"issue":"11","key":"10.3233\/JND-190426_ref24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1152\/physiolgenomics.00075.2016","article-title":"Transcriptome assessment of the Pompe (Gaa-\/-) mouse spinal cord indicates widespread neuropathology","volume":"48","author":"Turner","year":"2016","journal-title":"Physiol Genomics"},{"key":"10.3233\/JND-190426_ref25","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.resp.2016.02.007","article-title":"Neuropathology in respiratory-related motoneurons in young Pompe (Gaa(-\/-)) mice","volume":"227","author":"Turner","year":"2016","journal-title":"Respir Physiol Neurobiol"},{"issue":"3","key":"10.3233\/JND-190426_ref26","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1165\/rcmb.2014-0374OC","article-title":"Stimulation of Respiratory Motor Output and Ventilation in a Murine Model of Pompe Disease by Ampakines","volume":"53","author":"ElMallah","year":"2015","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"23","key":"10.3233\/JND-190426_ref27","doi-asserted-by":"crossref","first-page":"9419","DOI":"10.1073\/pnas.0902534106","article-title":"Neural deficits contribute to respiratory insufficiency in Pompe disease","volume":"106","author":"DeRuisseau","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.3233\/JND-190426_ref28","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1097\/NEN.0b013e3181815994","article-title":"Temporal neuropathologic and behavioral phenotype of 6neo\/6neo Pompe disease mice","volume":"67","author":"Sidman","year":"2008","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.3233\/JND-190426_ref29","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00005072-197107000-00008","article-title":"Nervous system in Pompe\u2019s disease. Ultrastructure and biochemistry","volume":"30","author":"Gambetti","year":"1971","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.3233\/JND-190426_ref30","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/00005072-196501000-00008","article-title":"Pompe\u2019s Disease (Diffuse Glycogenosis) with Neuronal Storage","volume":"24","author":"Mancall","year":"1965","journal-title":"J Neuropathol Exp Neurol"},{"issue":"3","key":"10.3233\/JND-190426_ref31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00687878","article-title":"Pompe\u2019s disease: An inborn lysosomal disorder with storage of glycogen. A study of brain and striated muscle","volume":"23","author":"Martin","year":"1973","journal-title":"Acta Neuropathol"},{"issue":"5","key":"10.3233\/JND-190426_ref32","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1212\/WNL.57.5.906","article-title":"Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2","volume":"57","author":"Martini","year":"2001","journal-title":"Neurology"},{"issue":"1","key":"10.3233\/JND-190426_ref33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.3233\/JND-190426_ref34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/bj0860011","article-title":"alpha-Glucosidase deficiency in generalized glycogenstorage disease (Pompe\u2019s disease)","volume":"86","author":"Hers","year":"1963","journal-title":"Biochem J"},{"issue":"2","key":"10.3233\/JND-190426_ref35","doi-asserted-by":"crossref","first-page":"73","DOI":"10.15252\/emmm.201505966","article-title":"The awesome lysosome","volume":"8","author":"Ballabio","year":"2016","journal-title":"EMBO Mol Med"},{"issue":"2","key":"10.3233\/JND-190426_ref36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41556-018-0244-7","article-title":"The lysosome as a cellular centre for signalling, metabolism and quality control","volume":"21","author":"Lawrence","year":"2019","journal-title":"Nat Cell Biol"},{"key":"10.3233\/JND-190426_ref37","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1146\/annurev-genet-102808-114910","article-title":"Regulation mechanisms and signaling pathways of autophagy","volume":"43","author":"He","year":"2009","journal-title":"Annu Rev Genet"},{"issue":"3","key":"10.3233\/JND-190426_ref38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/embor.2012.5","article-title":"Autophagy\u2013alias self-eating\u2013appetite and ageing","volume":"13","author":"Rubinsztein","year":"2012","journal-title":"EMBO Rep"},{"issue":"9","key":"10.3233\/JND-190426_ref39","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1038\/nrd3802","article-title":"Autophagy modulation as a potential therapeutic target for diverse diseases","volume":"11","author":"Rubinsztein","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.3233\/JND-190426_ref40","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1016\/j.cub.2011.11.034","article-title":"Mechanisms of autophagosome biogenesis","volume":"22","author":"Rubinsztein","year":"2012","journal-title":"Curr Biol"},{"key":"10.3233\/JND-190426_ref41","doi-asserted-by":"crossref","first-page":"xxiii","DOI":"10.1016\/S0076-6879(17)30062-9","article-title":"Preface","volume":"587","author":"Galluzzi","year":"2017","journal-title":"Methods Enzymol"},{"issue":"2","key":"10.3233\/JND-190426_ref42","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ceb.2009.11.014","article-title":"Mammalian autophagy: Core molecular machinery and signaling regulation","volume":"22","author":"Yang","year":"2010","journal-title":"Curr Opin Cell Biol"},{"issue":"5882","key":"10.3233\/JND-190426_ref43","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1126\/science.1157535","article-title":"The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1","volume":"320","author":"Sancak","year":"2008","journal-title":"Science"},{"issue":"2","key":"10.3233\/JND-190426_ref44","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2010.02.024","article-title":"Ragulator-Rag complex targets mTORC1 to the lysosomal surface and is necessary for its activation by amino acids","volume":"141","author":"Sancak","year":"2010","journal-title":"Cell"},{"issue":"2","key":"10.3233\/JND-190426_ref45","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/ncb2152","article-title":"AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1","volume":"13","author":"Kim","year":"2011","journal-title":"Nat Cell Biol"},{"issue":"6","key":"10.3233\/JND-190426_ref46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.4161\/auto.7.6.15123","article-title":"The autophagy initiating kinase ULK1 is regulated via opposing phosphorylation by AMPK and mTOR","volume":"7","author":"Egan","year":"2011","journal-title":"Autophagy"},{"issue":"24","key":"10.3233\/JND-190426_ref47","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.4161\/cc.8.24.10263","article-title":"Lysosomal enhancement: A CLEAR answer to cellular degradative needs","volume":"8","author":"Sardiello","year":"2009","journal-title":"Cell Cycle"},{"issue":"5939","key":"10.3233\/JND-190426_ref48","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"issue":"309","key":"10.3233\/JND-190426_ref49","doi-asserted-by":"crossref","first-page":"ra9","DOI":"10.1126\/scisignal.2004754","article-title":"The nutrient-responsive transcription factor TFE3 promotes autophagy, lysosomal biogenesis, and clearance of cellular debris","volume":"7","author":"Martina","year":"2014","journal-title":"Sci Signal"},{"key":"10.3233\/JND-190426_ref50","doi-asserted-by":"crossref","unstructured":"Puertollano R , et al. The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J. 2018;37(11).","DOI":"10.15252\/embj.201798804"},{"key":"10.3233\/JND-190426_ref51","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-cellbio-111315-125125","article-title":"The Lysosome as a Regulatory Hub","volume":"32","author":"Perera","year":"2016","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"4","key":"10.3233\/JND-190426_ref52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1080\/15548627.2019.1575162","article-title":"Spatially distinct pools of TORC1 balance protein homeostasis","volume":"15","author":"Lahiri","year":"2019","journal-title":"Autophagy"},{"issue":"1","key":"10.3233\/JND-190426_ref53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/jemt.20046","article-title":"Glycogen autophagy","volume":"64","author":"Kotoulas","year":"2004","journal-title":"Microsc Res Tech"},{"issue":"9","key":"10.3233\/JND-190426_ref54","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.prp.2006.04.001","article-title":"Glycogen autophagy in glucose homeostasis","volume":"202","author":"Kotoulas","year":"2006","journal-title":"Pathol Res Pract"},{"issue":"1","key":"10.3233\/JND-190426_ref55","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1083\/jcb.52.1.41","article-title":"Autophagic degradation of glycogen in skeletal muscles of the newborn rat","volume":"52","author":"Schiaffino","year":"1972","journal-title":"J Cell Biol"},{"issue":"5","key":"10.3233\/JND-190426_ref56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.15698\/cst2019.05.186","article-title":"Recent progress in the role of autophagy in neurological diseases","volume":"3","author":"Meng","year":"2019","journal-title":"Cell Stress"},{"issue":"5","key":"10.3233\/JND-190426_ref57","doi-asserted-by":"crossref","first-page":"719","DOI":"10.4161\/auto.19469","article-title":"Autophagy in lysosomal storage disorders","volume":"8","author":"Lieberman","year":"2012","journal-title":"Autophagy"},{"issue":"1","key":"10.3233\/JND-190426_ref58","doi-asserted-by":"crossref","first-page":"e1068978","DOI":"10.1080\/21675511.2015.1068978","article-title":"Pompe disease: Shared and unshared features of lysosomal storage disorders","volume":"3","author":"Lim","year":"2015","journal-title":"Rare Dis"},{"issue":"30","key":"10.3233\/JND-190426_ref59","doi-asserted-by":"crossref","first-page":"19086","DOI":"10.1074\/jbc.273.30.19086","article-title":"Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II","volume":"273","author":"Raben","year":"1998","journal-title":"J Biol Chem"},{"issue":"1","key":"10.3233\/JND-190426_ref60","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol"},{"issue":"6","key":"10.3233\/JND-190426_ref61","doi-asserted-by":"crossref","first-page":"546","DOI":"10.4161\/auto.4591","article-title":"Deconstructing Pompe disease by analyzing single muscle fibers: To see a world in a grain of sand","volume":"3","author":"Raben","year":"2007","journal-title":"Autophagy"},{"issue":"5","key":"10.3233\/JND-190426_ref62","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jbiomech.2004.05.040","article-title":"Effects of non-contractile inclusions on mechanical performance of skeletal muscle","volume":"38","author":"Drost","year":"2005","journal-title":"J Biomech"},{"issue":"3","key":"10.3233\/JND-190426_ref63","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.jsb.2008.03.010","article-title":"Detection and imaging of non-contractile inclusions and sarcomeric anomalies in skeletal muscle by second harmonic generation combined with two-photon excited fluorescence","volume":"162","author":"Ralston","year":"2008","journal-title":"J Struct Biol"},{"issue":"5","key":"10.3233\/JND-190426_ref64","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1152\/japplphysiol.01253.2009","article-title":"Impaired organization and function of myofilaments in single muscle fibers from a mouse model of Pompe disease","volume":"108","author":"Xu","year":"2010","journal-title":"J Appl Physiol"},{"issue":"5","key":"10.3233\/JND-190426_ref65","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/emmm.201202176","article-title":"Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease","volume":"5","author":"Spampanato","year":"2013","journal-title":"EMBO Mol Med"},{"issue":"7","key":"10.3233\/JND-190426_ref66","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.4161\/auto.24920","article-title":"What else is in store for autophagy? Exocytosis of autolysosomes as a mechanism of TFEB-mediated cellular clearance in Pompe disease","volume":"9","author":"Feeney","year":"2013","journal-title":"Autophagy"},{"issue":"1","key":"10.3233\/JND-190426_ref67","doi-asserted-by":"crossref","first-page":"17175","DOI":"10.1038\/s41598-017-17384-0","article-title":"mTORC1 Signaling is a Critical Regulator of Postnatal Tendon Development","volume":"7","author":"Lim","year":"2017","journal-title":"Sci Rep"},{"issue":"7","key":"10.3233\/JND-190426_ref68","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ymthe.2018.04.025","article-title":"Therapeutic Benefit of Autophagy Modulation in Pompe Disease","volume":"26","author":"Lim","year":"2018","journal-title":"Mol Ther"},{"issue":"5","key":"10.3233\/JND-190426_ref69","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nan.12214","article-title":"Impaired autophagy affects acid alpha-glucosidase processing and enzyme replacement therapy efficacy in late-onset glycogen storage disease type II","volume":"41","author":"Nascimbeni","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"8","key":"10.3233\/JND-190426_ref70","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4161\/auto.6.8.13378","article-title":"Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder\u2013murine Pompe disease","volume":"6","author":"Raben","year":"2010","journal-title":"Autophagy"},{"key":"10.3233\/JND-190426_ref71","doi-asserted-by":"crossref","unstructured":"Xu S , et al. Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight. 2019;4(5).","DOI":"10.1172\/jci.insight.125358"},{"key":"10.3233\/JND-190426_ref72","doi-asserted-by":"crossref","unstructured":"Puzzo F , et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid alpha-glucosidase. Sci Transl Med. 2017;9(418).","DOI":"10.1126\/scitranslmed.aam6375"},{"key":"10.3233\/JND-190426_ref73","doi-asserted-by":"crossref","unstructured":"McCall AL , et al. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy. Curr Gene Ther, 2019.","DOI":"10.2174\/1566523219666190621113807"},{"key":"10.3233\/JND-190426_ref74","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2016.08.003","article-title":"In vivo tissue-tropism of adeno-associated viral vectors","volume":"21","author":"Srivastava","year":"2016","journal-title":"Curr Opin Virol"},{"issue":"4","key":"10.3233\/JND-190426_ref75","doi-asserted-by":"crossref","first-page":"338","DOI":"10.2174\/1566523215666150630132253","article-title":"Preclinical Development of New Therapy for Glycogen Storage Diseases","volume":"15","author":"Sun","year":"2015","journal-title":"Curr Gene Ther"},{"issue":"9","key":"10.3233\/JND-190426_ref76","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1089\/hum.2010.245","article-title":"Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors","volume":"22","author":"Gray","year":"2011","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JND-190426_ref77","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1479-0556-6-13","article-title":"Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice","volume":"6","author":"Pacak","year":"2008","journal-title":"Genet Vaccines Ther"},{"issue":"2","key":"10.3233\/JND-190426_ref78","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/sj.mt.6300027","article-title":"Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle","volume":"15","author":"Salva","year":"2007","journal-title":"Mol Ther"},{"issue":"9","key":"10.3233\/JND-190426_ref79","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/mt.2013.96","article-title":"Intrapleural administration of AAV9 improves neural and cardiorespiratory function in Pompe disease","volume":"21","author":"Falk","year":"2013","journal-title":"Mol Ther"},{"issue":"5","key":"10.3233\/JND-190426_ref80","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1086\/522236","article-title":"Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance","volume":"81","author":"Sun","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.3233\/JND-190426_ref81","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.omtm.2018.11.002","article-title":"AAV Gene Transfer with Tandem Promoter Design Prevents Anti-transgene Immunity and Provides Persistent Efficacy in Neonate Pompe Mice","volume":"12","author":"Colella","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.3233\/JND-190426_ref82","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jconrel.2016.09.011","article-title":"Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9","volume":"241","author":"Saraiva","year":"2016","journal-title":"J Control Release"},{"key":"10.3233\/JND-190426_ref83","doi-asserted-by":"crossref","unstructured":"Byrne BJ , et al. Pompe disease gene therapy: Neural manifestations require consideration of CNS directed therapy. Annals of Translational Medicine, 2019.","DOI":"10.21037\/atm.2019.05.56"},{"issue":"3","key":"10.3233\/JND-190426_ref84","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/sj.mt.6300100","article-title":"Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors","volume":"15","author":"Mah","year":"2007","journal-title":"Mol Ther"},{"issue":"8","key":"10.3233\/JND-190426_ref85","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1038\/mt.2008.133","article-title":"Correction of multiple striated muscles in murine Pompe disease through adeno-associated virus-mediated gene therapy","volume":"16","author":"Sun","year":"2008","journal-title":"Mol Ther"},{"key":"10.3233\/JND-190426_ref86","doi-asserted-by":"crossref","first-page":"15007","DOI":"10.1038\/mtm.2015.7","article-title":"Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice","volume":"2","author":"Falk","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.3233\/JND-190426_ref87","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1161\/01.RES.0000237661.18885.f6","article-title":"Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo","volume":"99","author":"Pacak","year":"2006","journal-title":"Circ Res"},{"key":"10.3233\/JND-190426_ref88","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.omtm.2019.01.006","article-title":"Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid alpha-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease","volume":"12","author":"Lim","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.3233\/JND-190426_ref89","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/hum.2018.016","article-title":"Systemic Delivery of AAVB1-GAA Clears Glycogen and Prolongs Survival in a Mouse Model of Pompe Disease","volume":"30","author":"Keeler","year":"2019","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.3233\/JND-190426_ref90","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/hum.2005.16.68","article-title":"Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid alpha-glucosidase in a model of glycogen storage disease type II","volume":"16","author":"Cresawn","year":"2005","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.3233\/JND-190426_ref91","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ymthe.2005.04.024","article-title":"Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storage disease type II","volume":"12","author":"Franco","year":"2005","journal-title":"Mol Ther"},{"issue":"6","key":"10.3233\/JND-190426_ref92","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.ymthe.2005.01.012","article-title":"Correction of glycogen storage disease type II by an adeno-associated virus vector containing a muscle-specific promoter","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"issue":"5 Pt 1","key":"10.3233\/JND-190426_ref93","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1006\/mthe.2002.0580","article-title":"Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors","volume":"5","author":"Fraites","year":"2002","journal-title":"Mol Ther"},{"issue":"3","key":"10.3233\/JND-190426_ref94","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/mt.2009.305","article-title":"Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease","volume":"18","author":"Mah","year":"2010","journal-title":"Mol Ther"},{"issue":"4","key":"10.3233\/JND-190426_ref95","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/mt.2013.282","article-title":"Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice","volume":"22","author":"Elmallah","year":"2014","journal-title":"Mol Ther"},{"issue":"3","key":"10.3233\/JND-190426_ref96","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s10545-011-9404-7","article-title":"Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy","volume":"35","author":"van Gelder","year":"2012","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.3233\/JND-190426_ref97","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00455-009-9252-x","article-title":"Oropharyngeal dysphagia in infants and children with infantile Pompe disease","volume":"25","author":"Jones","year":"2010","journal-title":"Dysphagia"},{"issue":"6","key":"10.3233\/JND-190426_ref98","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/mus.22202","article-title":"Expanding the phenotype of late-onset Pompe disease: Tongue weakness: A new clinical observation","volume":"44","author":"Dubrovsky","year":"2011","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.3233\/JND-190426_ref99","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nmd.2012.12.003","article-title":"Oropharyngeal dysphagia may occur in late-onset Pompe disease, implicating bulbar muscle involvement","volume":"23","author":"Hobson-Webb","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"10.3233\/JND-190426_ref100","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1089\/hum.2012.250","article-title":"Phase I\/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: Initial safety and ventilatory outcomes","volume":"24","author":"Smith","year":"2013","journal-title":"Hum Gene Ther"},{"issue":"11","key":"10.3233\/JND-190426_ref101","doi-asserted-by":"crossref","first-page":"e112268","DOI":"10.1371\/journal.pone.0112268","article-title":"Intramuscular injection of AAV8 in mice and macaques is associated with substantial hepatic targeting and transgene expression","volume":"9","author":"Greig","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.3233\/JND-190426_ref102","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/mt.2008.87","article-title":"Safety and efficacy of regional intravenous (r.i.) versus intramuscular (i.m.) delivery of rAAV1 and rAAV8 to nonhuman primate skeletal muscle","volume":"16","author":"Toromanoff","year":"2008","journal-title":"Mol Ther"},{"issue":"1","key":"10.3233\/JND-190426_ref103","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s40478-017-0464-2","article-title":"Long-term neurologic and cardiac correction by intrathecal gene therapy in Pompe disease","volume":"5","author":"Hordeaux","year":"2017","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"10.3233\/JND-190426_ref104","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00415-018-9124-0","article-title":"Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients","volume":"266","author":"Wurster","year":"2019","journal-title":"J Neurol"},{"issue":"6","key":"10.3233\/JND-190426_ref105","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1007\/s12035-017-0763-4","article-title":"A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice","volume":"55","author":"Lee","year":"2018","journal-title":"Mol Neurobiol"},{"issue":"7","key":"10.3233\/JND-190426_ref106","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1089\/hum.2007.042","article-title":"Muscle as a target for supplementary factor IX gene transfer","volume":"18","author":"Hoffman","year":"2007","journal-title":"Hum Gene Ther"},{"issue":"9","key":"10.3233\/JND-190426_ref107","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1172\/JCI200316887","article-title":"Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer","volume":"111","author":"Mingozzi","year":"2003","journal-title":"J Clin Invest"},{"issue":"20","key":"10.3233\/JND-190426_ref108","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood-2009-05-217315","article-title":"Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy","volume":"114","author":"Peng","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.3233\/JND-190426_ref109","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.mt.6300146","article-title":"Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity","volume":"15","author":"Doering","year":"2007","journal-title":"Mol Ther"},{"issue":"2","key":"10.3233\/JND-190426_ref110","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/mt.2009.195","article-title":"Immunomodulatory gene therapy prevents antibody formation and lethal hypersensitivity reactions in murine pompe disease","volume":"18","author":"Sun","year":"2010","journal-title":"Mol Ther"},{"issue":"10","key":"10.3233\/JND-190426_ref111","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1016\/j.transproceed.2006.10.094","article-title":"Anti-CD25 mAb administration prevents spontaneous liver transplant tolerance","volume":"38","author":"Li","year":"2006","journal-title":"Transplant Proc"},{"issue":"4","key":"10.3233\/JND-190426_ref112","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1365-2222.2007.02681.x","article-title":"CD4+CD25+T cells regulate the intensity of hypersensitivity responses to peanut, but are not decisive in the induction of oral sensitization","volume":"37","author":"van Wijk","year":"2007","journal-title":"Clin Exp Allergy"},{"key":"10.3233\/JND-190426_ref113","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/mtm.2015.2","article-title":"Corrigendum to \u201cAssessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease\u201d","volume":"2","author":"Wang","year":"2015","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.3233\/JND-190426_ref114","doi-asserted-by":"crossref","first-page":"14018","DOI":"10.1038\/mtm.2014.18","article-title":"Assessment of toxicity and biodistribution of recombinant AAV8 vector-mediated immunomodulatory gene therapy in mice with Pompe disease","volume":"1","author":"Wang","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.3233\/JND-190426_ref115","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ymthe.2004.10.004","article-title":"Efficacy of an adeno-associated virus 8-pseudotyped vector in glycogen storage disease type II","volume":"11","author":"Sun","year":"2005","journal-title":"Mol Ther"},{"issue":"1","key":"10.3233\/JND-190426_ref116","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/hum.2014.115","article-title":"Enhanced efficacy from gene therapy in Pompe disease using coreceptor blockade","volume":"26","author":"Han","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.3233\/JND-190426_ref117","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ymgme.2011.11.005","article-title":"beta2 Agonists enhance the efficacy of simultaneous enzyme replacement therapy in murine Pompe disease","volume":"105","author":"Koeberl","year":"2012","journal-title":"Mol Genet Metab"},{"issue":"2","key":"10.3233\/JND-190426_ref118","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.02.006","article-title":"Enhanced efficacy of enzyme replacement therapy in Pompe disease through mannose-6-phosphate receptor expression in skeletal muscle","volume":"103","author":"Koeberl","year":"2011","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.3233\/JND-190426_ref119","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1096\/fj.12-207472","article-title":"Adjunctive beta2-agonists reverse neuromuscular involvement in murine Pompe disease","volume":"27","author":"Li","year":"2013","journal-title":"FASEB J"},{"issue":"5","key":"10.3233\/JND-190426_ref120","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1096\/fj.13-244202","article-title":"Adjunctive beta2-agonist treatment reduces glycogen independently of receptor-mediated acid alpha-glucosidase uptake in the limb muscles of mice with Pompe disease","volume":"28","author":"Farah","year":"2014","journal-title":"FASEB J"},{"issue":"1","key":"10.3233\/JND-190426_ref121","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2016.03.006","article-title":"Salmeterol enhances the cardiac response to gene therapy in Pompe disease","volume":"118","author":"Han","year":"2016","journal-title":"Mol Genet Metab"},{"issue":"5","key":"10.3233\/JND-190426_ref122","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1089\/hum.2011.063","article-title":"Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease","volume":"23","author":"Zhang","year":"2012","journal-title":"Hum Gene Ther"},{"key":"10.3233\/JND-190426_ref123","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.omtm.2016.12.010","article-title":"Low-Dose Liver-Targeted Gene Therapy for Pompe Disease Enhances Therapeutic Efficacy of ERT via Immune Tolerance Induction","volume":"4","author":"Han","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"1","key":"10.3233\/JND-190426_ref124","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/hum.2015.103","article-title":"Copackaged AAV9 Vectors Promote Simultaneous Immune Tolerance and Phenotypic Correction of Pompe Disease","volume":"27","author":"Doerfler","year":"2016","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.3233\/JND-190426_ref125","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1089\/humc.2014.2514","article-title":"Phase I\/II trial of diaphragm delivery of recombinant adeno-associated virus acid alpha-glucosidase (rAAaV1-CMV-GAA) gene vector in patients with Pompe disease","volume":"25","author":"Byrne","year":"2014","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.3233\/JND-190426_ref126","doi-asserted-by":"crossref","first-page":"16002","DOI":"10.1038\/mtm.2016.2","article-title":"Manufacturing of recombinant adeno-associated viral vectors for clinical trials","volume":"3","author":"Clement","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.3233\/JND-190426_ref127","volume-title":"Muscle Gene Therapy","author":"Clement","year":"2019"},{"issue":"Pt 2","key":"10.3233\/JND-190426_ref128","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.expneurol.2016.07.013","article-title":"Inspiratory muscle conditioning exercise and diaphragm gene therapy in Pompe disease: Clinical evidence of respiratory plasticity","volume":"287","author":"Smith","year":"2017","journal-title":"Exp Neurol"},{"issue":"3","key":"10.3233\/JND-190426_ref129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/humc.2015.068","article-title":"Evaluation of Readministration of a Recombinant Adeno-Associated Virus Vector Expressing Acid Alpha-Glucosidase in Pompe Disease: Preclinical to Clinical Planning","volume":"26","author":"Corti","year":"2015","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"8","key":"10.3233\/JND-190426_ref130","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1089\/hum.2009.004","article-title":"Scalable recombinant adeno-associated virus production using recombinant herpes simplex virus type 1 coinfection of suspension-adapted mammalian cells","volume":"20","author":"Thomas","year":"2009","journal-title":"Hum Gene Ther"},{"issue":"1","key":"10.3233\/JND-190426_ref131","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2016.151","article-title":"Sodium Chloride Enhances Recombinant Adeno-Associated Virus Production in a Serum-Free Suspension Manufacturing Platform Using the Herpes Simplex Virus System","volume":"28","author":"Adamson-Small","year":"2017","journal-title":"Hum Gene Ther Methods"},{"issue":"Pt 1","key":"10.3233\/JND-190426_ref132","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1099\/vir.0.067108-0","article-title":"Thirty years of baculovirus-insect cell protein expression: From dark horse to mainstream technology","volume":"96","author":"van Oers","year":"2015","journal-title":"J Gen Virol"},{"key":"10.3233\/JND-190426_ref133","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.omtm.2018.01.002","article-title":"Pharmacology of Recombinant Adeno-associated Virus Production","volume":"8","author":"Penaud-Budloo","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.3233\/JND-190426_ref134","unstructured":"Ertl HCJ . Preclinical models to assess the immunogenicity of AAV vectors. Cell Immunol, 2017."},{"issue":"4","key":"10.3233\/JND-190426_ref135","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1089\/hum.2016.172","article-title":"Impact of AAV Capsid-Specific T-Cell Responses on Design and Outcome of Clinical Gene Transfer Trials with Recombinant Adeno-Associated Viral Vectors: An Evolving Controversy","volume":"28","author":"Ertl","year":"2017","journal-title":"Hum Gene Ther"},{"issue":"2","key":"10.3233\/JND-190426_ref136","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/hgtb.2015.037","article-title":"Determination of anti-adeno-associated virus vector neutralizing antibody titer with an in vitro reporter system","volume":"26","author":"Meliani","year":"2015","journal-title":"Hum Gene Ther Methods"},{"issue":"194","key":"10.3233\/JND-190426_ref137","doi-asserted-by":"crossref","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming preexisting humoral immunity to AAV using capsid decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci Transl Med"},{"issue":"4","key":"10.3233\/JND-190426_ref138","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/gt.2012.55","article-title":"Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue","volume":"20","author":"Mingozzi","year":"2013","journal-title":"Gene Ther"},{"issue":"1","key":"10.3233\/JND-190426_ref139","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1182\/blood-2013-01-306647","article-title":"Immune responses to AAV vectors: Overcoming barriers to successful gene therapy","volume":"122","author":"Mingozzi","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.3233\/JND-190426_ref140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/hum.2013.169","article-title":"Immune responses to intramuscular administration of alipogene tiparvovec (AAV1-LPL(S447X)) in a phase II clinical trial of lipoprotein lipase deficiency gene therapy","volume":"25","author":"Ferreira","year":"2014","journal-title":"Hum Gene Ther"},{"issue":"10","key":"10.3233\/JND-190426_ref141","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.3233\/JND-190426_ref142","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/sj.mt.6300334","article-title":"Prolonged susceptibility to antibody-mediated neutralization for adeno-associated vectors targeted to the liver","volume":"16","author":"Murphy","year":"2008","journal-title":"Mol Ther"},{"issue":"3","key":"10.3233\/JND-190426_ref143","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"10.3233\/JND-190426_ref144","first-page":"1","article-title":"B-Cell Depletion is Protective Against Anti-AAV Capsid Immune Response: A Human Subject Case Study","author":"Corti","year":"2014","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"4","key":"10.3233\/JND-190426_ref145","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1089\/humc.2017.146","article-title":"Safety of Intradiaphragmatic Delivery of Adeno-Associated Virus-Mediated Alpha-Glucosidase (rAAV1-CMV-hGAA) Gene Therapy in Children Affected by Pompe Disease","volume":"28","author":"Corti","year":"2017","journal-title":"Hum Gene Ther Clin Dev"},{"key":"10.3233\/JND-190426_ref146","first-page":"32","article-title":"Immune Blockade in CNS Gene Therapy Improves Safety and Clinical Outcome","volume":"26","author":"Corti","year":"2018","journal-title":"Molecular Therapy"},{"issue":"1","key":"10.3233\/JND-190426_ref147","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-selective modulation of AAV immunogenicity with tolerogenic rapamycin nanoparticles enables successful vector re-administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"issue":"2","key":"10.3233\/JND-190426_ref148","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther"},{"issue":"11","key":"10.3233\/JND-190426_ref149","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/mt.2011.108","article-title":"A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol Ther"},{"issue":"6","key":"10.3233\/JND-190426_ref150","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: Implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10.3233\/JND-190426_ref151","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/hmg\/ddu476","article-title":"Peripheral nerve and neuromuscular junction pathology in Pompe disease","volume":"24","author":"Falk","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"6","key":"10.3233\/JND-190426_ref152","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mus.24444","article-title":"Altered activation of the tibialis anterior in individuals with Pompe disease: Implications for motor unit dysfunction","volume":"51","author":"Corti","year":"2015","journal-title":"Muscle Nerve"},{"issue":"4","key":"10.3233\/JND-190426_ref153","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/WNP.0000000000000084","article-title":"Are evoked potentials in patients with adult-onset pompe disease indicative of clinically relevant central nervous system involvement?","volume":"31","author":"Wirsching","year":"2014","journal-title":"J Clin Neurophysiol"},{"issue":"3","key":"10.3233\/JND-190426_ref154","doi-asserted-by":"crossref","first-page":"442-e35","DOI":"10.1111\/ene.13835","article-title":"Central nervous system involvement in late-onset Pompe disease: Clues from neuroimaging and neuropsychological analysis","volume":"26","author":"Musumeci","year":"2019","journal-title":"Eur J Neurol"},{"issue":"10","key":"10.3233\/JND-190426_ref155","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1007\/s00415-017-8601-1","article-title":"Late-onset Pompe disease: A genetic-radiological correlation on cerebral vascular anomalies","volume":"264","author":"Pichiecchio","year":"2017","journal-title":"J Neurol"},{"issue":"3","key":"10.3233\/JND-190426_ref156","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s10545-015-9913-x","article-title":"Intracranial arterial abnormalities in patients with late onset Pompe disease (LOPD)","volume":"39","author":"Montagnese","year":"2016","journal-title":"J Inherit Metab Dis"},{"key":"10.3233\/JND-190426_ref157","doi-asserted-by":"crossref","first-page":"713","DOI":"10.2147\/NDT.S94892","article-title":"Late-onset Pompe disease with complicated intracranial aneurysm: A Chinese case report","volume":"12","author":"Zhang","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"8","key":"10.3233\/JND-190426_ref158","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/STROKEAHA.118.021964","article-title":"Association of Low Lysosomal Enzymes Activity With Brain Arterial Dilatation","volume":"49","author":"Shah","year":"2018","journal-title":"Stroke"},{"issue":"6","key":"10.3233\/JND-190426_ref159","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/dmcn.13740","article-title":"Classic infantile Pompe patients approaching adulthood: A cohort study on consequences for the brain","volume":"60","author":"Ebbink","year":"2018","journal-title":"Dev Med Child Neurol"},{"issue":"2","key":"10.3233\/JND-190426_ref160","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ymgme.2017.10.005","article-title":"Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy","volume":"123","author":"McIntosh","year":"2018","journal-title":"Mol Genet Metab"},{"issue":"1","key":"10.3233\/JND-190426_ref161","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13023-018-0771-0","article-title":"Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy","volume":"13","author":"Parini","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.3233\/JND-190426_ref162","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/ana.24433","article-title":"Correcting Neuromuscular Deficits With Gene Therapy in Pompe Disease","volume":"78","author":"Todd","year":"2015","journal-title":"Ann Neurol"},{"issue":"11","key":"10.3233\/JND-190426_ref163","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1089\/hum.2015.033","article-title":"Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a beta2-Agonist in Murine Pompe Disease","volume":"26","author":"Han","year":"2015","journal-title":"Hum Gene Ther"},{"issue":"11","key":"10.3233\/JND-190426_ref164","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/jgm.1511","article-title":"Antibody formation and mannose-6-phosphate receptor expression impact the efficacy of muscle-specific transgene expression in murine Pompe disease","volume":"12","author":"Sun","year":"2010","journal-title":"J Gene Med"},{"issue":"6","key":"10.3233\/JND-190426_ref165","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.ymthe.2006.08.001","article-title":"Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II","volume":"14","author":"Sun","year":"2006","journal-title":"Mol Ther"},{"issue":"4","key":"10.3233\/JND-190426_ref166","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1089\/humc.2016.119","article-title":"Transfer of Therapeutic Genes into Fetal Rhesus Monkeys Using Recombinant Adeno-Associated Type I Viral Vectors","volume":"27","author":"Conlon","year":"2016","journal-title":"Hum Gene Ther Clin Dev"},{"issue":"1","key":"10.3233\/JND-190426_ref167","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/mt.2011.214","article-title":"Spinal delivery of AAV vector restores enzyme activity and increases ventilation in Pompe mice","volume":"20","author":"Qiu","year":"2012","journal-title":"Mol Ther"},{"issue":"8","key":"10.3233\/JND-190426_ref168","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1089\/hum.2012.140","article-title":"Gene therapy approaches for lysosomal storage disease: Next-generation treatment","volume":"23","author":"Byrne","year":"2012","journal-title":"Hum Gene Ther"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-190426","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:24Z","timestamp":1777506564000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-190426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,22]]},"references-count":168,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.3233\/jnd-190426","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,22]]}}}